Cargando…
A recombinant HER2/neu expressing listeria monocytogenes (Lm-LLO) immunotherapy delays metastatic disease and prolongs overall survival in a spontaneous canine model of osteosarcoma - a Phase I clinical trial
Autores principales: | Gnanandarajah, Josephine S, Ndikuyeze, Georges Habineza, Engiles, Julie B, Wallecha, Anu, Mason, Nicola |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288668/ http://dx.doi.org/10.1186/2051-1426-2-S3-P55 |
Ejemplares similares
-
Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy
por: Mkrtichyan, Mikayel, et al.
Publicado: (2013) -
Listeria monocytogenes (Lm)-LLO immunotherapies reduce the immunosuppressive activity of myeloid-derived suppressor cells and regulatory T cells in the tumor microenvironment
por: Wallecha, Anu, et al.
Publicado: (2013) -
Lm-LLO-Based Immunotherapies and HPV-Associated Disease
por: Wallecha, Anu, et al.
Publicado: (2012) -
Lm-LLO immunotherapies targeting multiple antigens and their impact on different mechanisms in the tumor microenvironment
por: Wallecha, Anu, et al.
Publicado: (2014) -
High-dose treatment with ADXS11-001, a listeria monocytogenes (Lm)-listeriolysin O (LLO) immunotherapy, in women with cervical cancer
por: Ghamande, Sharad, et al.
Publicado: (2015)